Drug Profile
Tc 99m besilesomab - IBA
Alternative Names: 99Tcm-BW250-183; BW 250 183; Scintimun; Tc 99m-labeled monoclonal antibody BW 250/183; Technetium-99m-antigranulocyte antibody BW 250-183; TLX66-CDxLatest Information Update: 12 Jun 2015
Price :
$50
*
At a glance
- Originator CIS bio international
- Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bone metastases; Infections; Inflammation; Osteomyelitis
Most Recent Events
- 12 Jun 2015 Launched for Osteomyelitis (Diagnosis) in Austria, Belgium, Croatia, Finland, Germany, Latvia, Italy, Lithuania, Malta, Slovenia and Slovakia (IV) before June 2015
- 23 Oct 2009 The Committee for Medicinal Products for Human Use recommends approval of Tc 99m besilesomab for Osteomyelitis diagnosis in the EU